Product Information
SB202190 is supplied as a lyophilized powder. For a 10 mM stock, reconstitute the 5 mg in 1.51 ml DMSO. Working concentrations and length of treatment can vary depending on the desired effect, but it is typically used as a pretreatment at 5-20 µM for 1-2 hours prior to treating with a stimulator. Soluble in DMSO, solubility in other solvents has not been evaluated.
| Molecular Weight | 331.4 g/mol |
| Purity | >98% |
| Molecular Formula | C20H14FN3O |
| CAS | 152121-30-7 |
| Solubility | Soluble in DMSO at 30mg/ml. |
SB202190, a pyridinyl imidazole, inhibits p38 MAP kinase activity through competition with ATP (1), and has been shown to induce apoptosis through activation of cysteine protease (CPP32)-like caspases (2). SB202190 blocks both lipopolysaccharide (LPS)-induced gene expression and nitric oxide (NO)-induced stabilization of interleukin (IL)-8 mRNA in monocytes (3,4). Pre-treatment of cells with SB202190 has been shown to inhibit phosphorylation of p38 MAPK despite exposure to anisomycin, a known inducer of the MAPK pathway (5). Of note, the mechanism of inhibition of SB202190 is unlike the one seen with SB203580, which inhibits p38 MAPK catalytic activity by binding to the ATP binding pocket, but does not inhibit phosphorylation of p38 MAPK by upstream kinases (6).
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
| Cat. # | Size | Qty. | Price |
|---|---|---|---|
| 8158S | 5 mg |
|
